Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Imig JD.

Physiol Rev. 2012 Jan;92(1):101-30. doi: 10.1152/physrev.00021.2011. Review.

2.

Targeting epoxides for organ damage in hypertension.

Imig JD.

J Cardiovasc Pharmacol. 2010 Oct;56(4):329-35. doi: 10.1097/FJC.0b013e3181e96e0c. Review.

3.

Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.

Elmarakby AA.

Am J Physiol Regul Integr Comp Physiol. 2012 Feb 1;302(3):R321-30. doi: 10.1152/ajpregu.00606.2011. Epub 2011 Nov 23. Review.

4.

Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.

Morisseau C, Hammock BD.

Annu Rev Pharmacol Toxicol. 2013;53:37-58. doi: 10.1146/annurev-pharmtox-011112-140244. Epub 2012 Sep 27. Review.

5.

Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.

Marowsky A, Burgener J, Falck JR, Fritschy JM, Arand M.

Neuroscience. 2009 Oct 6;163(2):646-61. doi: 10.1016/j.neuroscience.2009.06.033. Epub 2009 Jun 18.

PMID:
19540314
6.

Epoxyeicosatrienoic acid analogs and vascular function.

Sudhahar V, Shaw S, Imig JD.

Curr Med Chem. 2010;17(12):1181-90. Review.

7.

Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.

Larsen BT, Miura H, Hatoum OA, Campbell WB, Hammock BD, Zeldin DC, Falck JR, Gutterman DD.

Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-9. Epub 2005 Oct 28.

8.

Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.

Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB.

Am J Physiol Renal Physiol. 2011 Oct;301(4):F765-72. doi: 10.1152/ajprenal.00201.2011. Epub 2011 Jul 13.

9.

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL.

Circ Res. 2000 Nov 24;87(11):992-8.

10.

Epoxyeicosanoids promote organ and tissue regeneration.

Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML, Lee CR, Benny O, Mudge DK, Butterfield CE, Mammoto A, Mammoto T, Inceoglu B, Jenkins RL, Simpson MA, Akino T, Lih FB, Tomer KB, Ingber DE, Hammock BD, Falck JR, Manthati VL, Kaipainen A, D'Amore PA, Puder M, Zeldin DC, Kieran MW.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13528-33. doi: 10.1073/pnas.1311565110. Epub 2013 Jul 29.

11.

Soluble epoxide hydrolase inhibitors and cardiovascular diseases.

Wang ZH, Davis BB, Jiang DQ, Zhao TT, Xu DY.

Curr Vasc Pharmacol. 2013 Jan;11(1):105-11. Review.

PMID:
22303912
12.

Sexually dimorphic adaptation of cardiac function: roles of epoxyeicosatrienoic acid and peroxisome proliferator-activated receptors.

Qin J, Le Y, Froogh G, Kandhi S, Jiang H, Luo M, Sun D, Huang A.

Physiol Rep. 2016 Jun;4(12). pii: e12838. doi: 10.14814/phy2.12838.

13.

Arachidonic acid cytochrome P450 epoxygenase pathway.

Spector AA.

J Lipid Res. 2009 Apr;50 Suppl:S52-6. doi: 10.1194/jlr.R800038-JLR200. Epub 2008 Oct 23. Review.

14.

Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.

Dalle Vedove F, Fava C, Jiang H, Zanconato G, Quilley J, Brunelli M, Guglielmi V, Vattemi G, Minuz P.

J Hypertens. 2016 Jul;34(7):1364-70. doi: 10.1097/HJH.0000000000000942.

15.

Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.

Spector AA, Fang X, Snyder GD, Weintraub NL.

Prog Lipid Res. 2004 Jan;43(1):55-90. Review.

PMID:
14636671
16.

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Imig JD, Hammock BD.

Nat Rev Drug Discov. 2009 Oct;8(10):794-805. doi: 10.1038/nrd2875. Review.

17.

Vascular pharmacology of epoxyeicosatrienoic acids.

Pfister SL, Gauthier KM, Campbell WB.

Adv Pharmacol. 2010;60:27-59. doi: 10.1016/B978-0-12-385061-4.00002-7. Review.

18.

Soluble epoxide hydrolase: gene structure, expression and deletion.

Harris TR, Hammock BD.

Gene. 2013 Sep 10;526(2):61-74. doi: 10.1016/j.gene.2013.05.008. Epub 2013 May 20. Review.

19.

Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Spector AA, Kim HY.

Biochim Biophys Acta. 2015 Apr;1851(4):356-65. doi: 10.1016/j.bbalip.2014.07.020. Epub 2014 Aug 2. Review.

20.

Diabetic CVD--soluble epoxide hydrolase as a target.

Lorthioir A, Guerrot D, Joannides R, Bellien J.

Cardiovasc Hematol Agents Med Chem. 2012 Sep;10(3):212-22. Review.

PMID:
22632263

Supplemental Content

Support Center